Success Stories: A Chemical Biologist Hailing from China Wins NIW Approval without RFE, in Less Than 3 Months with Our Diligent Service
Client’s Testimonial:
“Staff members of NAmILG are extremely professional and efficient. Both my spouse and I hired them, and we are very satisfied with their services. Highly recommended to others!”
On April 8th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Chemical Biologist in the Field of Chemical Biology (Approval Notice).
General Field: Chemical Biology
Position at the Time of Case Filing: Chemical Biologist
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: April 8th, 2022
Processing Time: 2 months, 29 days
Case Summary:
As an expert in the field of chemical biology, our NIW (National Interest Waiver) client’s proposed endeavor was to continue his research on the development of chemical biology tools to explore protein function in order to discover important therapeutics for serious lung diseases. It became apparent to our team very soon that the work he was conducting was of significance to the U.S.A. This was so because his work addresses the need for improved treatments for respiratory infections and diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), cystic fibrosis (CF), and COVID-19.
His proposed endeavor also has broad implications for the United States due to the very same reason. At the same time, due to its clear national importance, his research has in fact been supported with funding from the National Institutes of Health in the form of multiple grants. The client has also completed at least 62 reviews to date. Given that only the most highly esteemed researchers in the field are invited to evaluate the work of their peers, especially in notable venues like these, it was clear that he is seen as very knowledgeable in the field and an expert in topics related to his proposed endeavor.
On the other hand, his research has resulted in 9 peer-reviewed journal articles (7 of them first-authored). Not only has he successfully completed and published the results of his research in the field, but his research has also gone on to influence his peers. That is, his publications have been cited a total of 228 times according to Google Scholar. The outstanding rates at which his papers have been cited indicate that others in his discipline have relied on his results to an exceptional degree. His study has also been supported by funding from the National Natural Science Foundation of China and the Major State Basic Research and Development Program of China. Due to its clear implications for fighting against the current COVID-19 pandemic, his research has also already attracted the attention of the private sector. With evidence of 5 fundings to his name, he stood tall above others in his field. His major funding sources were the National Institutes of Health, the National Natural Science Foundation of China; the Major State Basic Research and Development Program of China, and the Chan Zuckerberg Initiative. This further showed that he was indeed a valued asset to the global scientific community.
Thus, when his case was approved less than 3 months from filing, we rejoiced in his victory. We are glad to have worked with him and we wish him all the best.